Which pharma companies are ready for diagnostic integration in 2017? | Diaceutics

Which pharma companies are ready for diagnostic integration in 2017?

April 4th, 2017

The regular Pharma Readiness reports produced by Diaceutics aim to capture a snapshot of the diagnostic and precision medicine industries at certain times in a fast-evolving landscape. Pharma Readiness for Diagnostic Integration 2017 is no exception and discusses such vital topics as:

  • Trends, best practice and preferred organizational styles in diagnostics (Dx) and precision medicine (PM)
  • Therapies in the pipeline
  • The impact of pharma readiness and financial risks
  • The companies that are pushing forward
  • Key takeaways and predictions

Production of this year’s report involved analysing 23 main pharma companies and the PM credentials of over 1000 therapies on the market and in the pipeline, providing a 360° view of Dx-dependent therapy assets. The benchmarking process is continually being refined to provide the most important industry insights. New analytical additions for 2017 include:

  • Analysis of therapy portfolios which are highly Dx-enabled, for example, hepatitis and diabetes
  • Scoring companies’ internal capability according to our “Like it/Learn it/Leverage it” to reflect with more granularity the impact of organizational structures on commercial performance
  • Inclusion of Big Data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of PM beyond molecular testing
  • Ranking of real-time experience with test launches

Being at the heart of the diagnostics space, Diaceutics is perfectly placed to not only analyse and comment on the precision medicine world in real-time but to make informed and thought-provoking predictions for the years ahead. So in addition to concise predictions around segmentation, partnering, the role of laboratories and Dx-enablement strategies, the 2017 report also contains a series of specially commissioned opinion pieces looking at the key trends likely to shape the pharma/Dx interface and PM marketplace to 2020 and beyond.

For an informed view of the current diagnostic landscape, the companies forging ahead and a look ahead at future trends, download Pharma Readiness for Diagnostic Integration 2017.

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications